COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition

被引：106

作者：

Zaharevitz, DW ^{[1
]}

Holbeck, SL ^{[1
]}

Bowerman, C ^{[1
]}

Svetlik, PA ^{[1
]}

机构：

[1] NCI, Informat Technol Branch, Dev Therapeut Program, Bethesda, MD 20892 USA

来源：

JOURNAL OF MOLECULAR GRAPHICS & MODELLING | 2002年 / 20卷 / 04期

关键词：

cell-based screening; correlation analysis; COMPARE; drug discovery; antitumor drugs;

D O I：

10.1016/S1093-3263(01)00126-7

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

For more than 10 years the National Cancer Institute (NCI) has tested compounds for their ability to inhibit the growth of human tumor cell lines in culture (NCI screen). Work of Ken Paull [J. Natl. Cancer Inst. 81 (1989) 1088] demonstrated that compounds with similar mechanism of cell growth inhibition show similar patterns of activity in the NCI screen. This observation was developed into an algorithm called COMPARE and has been successfully used to predict mechanisms for a wide variety of compounds. More recently, this method has been extended to associate patterns of cell growth inhibition by compounds with measurements of molecular entities (such as gene expression) in the cell lines in the NCI screen. The COMPARE method and associated data are freely available on the Developmental Therapeutics Program (DTP) web site (http://dtp.nei.nih.gov/). Examples of the use of COMPARE on these web pages will be explained and demonstrated. Published by Elsevier Science Inc.

引用

页码：297 / 303

页数：7

共 22 条

[1] GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN [J].

ALVAREZ, M ;

PAULL, K ;

MONKS, A ;

HOSE, C ;

LEE, JS ;

WEINSTEIN, J ;

GREVER, M ;

BATES, S ;

FOJO, T .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2205-2214

[2]

BOYD MR, 1992, DEV ONCOL, V68, P11

[3] Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar [J].

Cleaveland, ES ;

Zaharevitz, DW ;

Kelley, JA ;

Paull, K ;

Cooney, DA ;

Ford, H .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 223 (03) :654-659

[4] SITE OF ACTION OF 2 NOVEL PYRIMIDINE BIOSYNTHESIS INHIBITORS ACCURATELY PREDICTED BY THE COMPARE PROGRAM [J].

CLEAVELAND, ES ;

MONKS, A ;

VAIGROWOLFF, A ;

ZAHAREVITZ, DW ;

PAULL, K ;

ARDALAN, K ;

COONEY, DA ;

FORD, H .

BIOCHEMICAL PHARMACOLOGY, 1995, 49 (07) :947-954

[5] A SYNTHETIC INHIBITOR OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE [J].

DUDLEY, DT ;

PANG, L ;

DECKER, SJ ;

BRIDGES, AJ ;

SALTIEL, AR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7686-7689

[6] Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor [J].

Duesbery, NS ;

Webb, CP ;

Leppla, SH ;

Gordon, VM ;

Klimpel, KR ;

Copeland, TD ;

Ahn, NG ;

Oskarsson, MK ;

Fukasawa, K ;

Paull, KD ;

Vande Woude, GF .

SCIENCE, 1998, 280 (5364) :734-737

[7]

Foye W. O, 1995, CANC CHEMOTHERAPEUTI, P9

[8] Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines [J].

Freije, JMP ;

Lawrence, JA ;

Hollingshead, MG ;

DeLaRosa, A ;

Narayanan, V ;

Grever, M ;

Sausville, EA ;

Paull, K ;

Steeg, PS .

NATURE MEDICINE, 1997, 3 (04) :395-401

[9] CYTOTOXICITY AND CHARACTERIZATION OF AN ACTIVE METABOLITE OF BENZAMIDE RIBOSIDE, A NOVEL INHIBITOR OF IMP DEHYDROGENASE [J].

GHAREHBAGHI, K ;

PAULL, KD ;

KELLEY, JA ;

BARCHI, JJ ;

MARQUEZ, VE ;

COONEY, DA ;

MONKS, A ;

SCUDIERO, D ;

KROHN, K ;

JAYARAM, HN .

INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (06) :892-899

[10] Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison [J].

Kohlhagen, G ;

Paull, KD ;

Cushman, M ;

Nagafuji, P ;

Pommier, Y .

MOLECULAR PHARMACOLOGY, 1998, 54 (01) :50-58

← 1 2 3 →